Trial · NCT06668805
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 35
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Annualized Growth Velocity (AGV) | At 6 months | |
| Secondary | Incidence of treatment-emergent adverse events | Until the end of the study, up to 15 years | |
| Secondary | Incidence of new diagnosis of hypertrophic cardiomyopathy in children with Noonan syndrome | Every 12 months through the end of the study, up to 15 years | |
| Secondary | Incidence of cardiac conditions requiring discontinuation of study treatment | Every 12 months through the end of the study, up to 15 years | |
| Secondary | Change from baseline in height | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Change from baseline in height Z-score | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Change from baseline in 12-month interval AGV | Until the end of the study, up to 15 years | |
| Secondary | Change from baseline in upper to lower body segment ratio | Until the end of the study, up to 15 years | |
| Secondary | Change from baseline in arm span to height ratio | Until the end of the study, up to 15 years | |
| Secondary | Change from baseline in height up to Final Adult Height (FAH) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Change from baseline in height Z-score up to FAH | Every 6 months through the end of the study, up to 15 years | |
| Secondary | 12-month interval AGV summarized by age and sex up to FAH | Every 12 months through the end of the study, up to 15 years | |
| Secondary | Tanner stage over the course of the study | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Time vosoritide is present at maximum concentration (Tmax) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Maximum vosoritide observed plasma concentration (Cmax) | Every 6 months through he end of the study, up to15 years | |
| Secondary | Area under the plasma vosoritide concentration time-curve from time 0 to the last measurable concentration (AUC0-t) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Area under the plasma vosoritide concentration time-curve from time 0 to infinity (AUC0-∞) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Elimination half-life of vosoritide (t½) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Apparent clearance of vosoritide (CL/F) | Every 6 months through the end of the study, up to 15 years | |
| Secondary | Apparent volume of distribution of vosoritide (Vz/F) | Every 6 months through the end of the study, up to 15 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06668805/registered